BioNTech Flags Limited Role For Trastuzumab Pamirtecan After Phase 3 Breast Cancer Readout And ILD Cases

BioNTech said its HER2-directed antibody-drug conjugate trastuzumab pamirtecan may offer only “limited” benefit in the current treatment setting after a phase 3 breast cancer trial delivered a statistically significant but modest efficacy result alongside unexpected safety findings. The readout is notable not just because the study met a progression-free survival bar, but because the company itself cast doubt on the program’s competitive value.

The trial, DYNASTY-Breast02, enrolled patients with HR-positive, HER2-low metastatic breast cancer. BioNTech developed trastuzumab pamirtecan, or t-pam, with DualityBiologics. The drug uses the same anti-HER2 antibody as AstraZeneca and Daiichi Sankyo’s Enhertu, with different linker technology and cytotoxic payload intended to differentiate it.

The Data

BioNTech reported a statistically significant improvement in progression-free survival versus chemotherapy in DYNASTY-Breast02, but described the gain as modest. The company did not provide details on the magnitude of the PFS benefit in its press release. BMO Capital Markets said a statistically significant PFS advantage had been “largely expected” and interpreted the lack of detail as “an incremental negative.”

Safety may be the more consequential issue. BioNTech said the study showed a higher rate of interstitial lung disease than seen in earlier t-pam trials. Most ILD cases were grade 1 or 2, but the company also said a “small proportion of patients” had severe or fatal events. It did not provide additional detail on the dataset or on implications for other ADCs in its portfolio.

BMO Capital Markets said physician sensitivity to pulmonary toxicity in HER2-directed ADCs is likely to weigh on the drug’s competitive position. The firm added that the phase 3 result lowers its confidence in the overall positioning of t-pam in HR+/HER2-low metastatic breast cancer.

The Strategic Picture

BioNTech’s own wording suggests the company is reassessing whether this indication remains worth pursuing. The company said it and DualityBio will review the data and decide next steps. BMO interpreted that stance as a sign t-pam is less likely to move forward in this setting.

Overall survival data were immature at the interim analysis, limiting the case for a broader salvage argument based on longer-term benefit. The setup is commercially awkward because Enhertu already defined the HER2-low category, leaving BioNTech needing either clearly better efficacy, a differentiated safety profile or a strategic filing path that still makes sense despite a smaller opportunity.

That filing path is also in question outside breast cancer. BioNTech already has data from a registrational cohort of endometrial carcinoma patients. TD Cowen said last week that a filing in endometrial carcinoma technically remains on track for 2026, but the firm suspected BioNTech would not seek approval in that indication alone because of the small market size and would instead wait to include breast cancer data.

The readout lands two weeks after BioNTech’s mRNA cancer vaccine BNT113 missed one of its dual primary endpoints in a phase 2/3 trial. Near term, that leaves greater attention on gotistobart and, over a longer horizon, on the PD-L1xVEGF-A bispecific pumitamig, which BioNTech recently highlighted with combination data involving a B7-H3-directed ADC at the European Society for Medical Oncology conference.